Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.81 |
| ▸ | CCND1 | P24385 | 16/20 | 0.81 |
| ▸ | CCND2 | P30279 | 14/20 | 0.81 |
| ▸ | CCND3 | P30281 | 14/20 | 0.81 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.81 |
| ▸ | CDK2 | P24941 | 9/20 | 0.81 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.81 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.70 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.70 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.70 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.70 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.70 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.66 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.66 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.66 |
| ▸ | CDK1 | P06493 | 3/20 | 0.66 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.66 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188925 | 0.91 | CDK4 (0.80) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL4529916 | 0.90 | CDK4 (0.71) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL4520642 | 0.84 | CDK4 (0.77) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL7712930 | 0.83 | CDK4 (0.80) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL22280544 | 0.82 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL31073169 | 0.82 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL17322466 | 0.81 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL6944231 | 0.81 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL13398462 | 0.81 | CDK4 (0.73) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL7071397 | 0.80 | CDK4 (0.98) | CDK4CCND1CCND2CCND3CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | CDK4 4/4885CCND1 615/4885CCND2 629/4885 |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | PRKDC, TK2, PNKP | CDK4 4/4885CCND1 615/4885CCND2 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.